UBS Group
SABS icon

UBS Group’s SAB Biotherapeutics SABS Stock Holding History

UBS Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.68M Buy
530,587
+164,709
+45% +$599K ﹤0.01% 5174
2026
Q2 		$1.43M Buy
365,878
+319,255
+685% +$1.19M ﹤0.01% 5417
2026
Q1 		$179K Buy
46,623
+39,225
+530% +$156K ﹤0.01% 6697
2025
Q4 		$27.7K Sell
7,398
-5,823
-44% -$19.2K ﹤0.01% 7578
2025
Q3 		$26.6K Buy
13,221
+2,563
+24% +$5.79K ﹤0.01% 7977
2025
Q2 		$18.7K Buy
10,658
+10,580
+13,564% +$17.5K ﹤0.01% 8491
2025
Q1 		$106 Sell
78
-1,005
-93% -$2.3K ﹤0.01% 9939
2024
Q4 		$4.11K Buy
+1,083
New +$3.56K ﹤0.01% 8789
2024
Q1 		– Sell
-50
Closed -$344 – 9924
2023
Q4 		$344 Buy
+50
New +$419 ﹤0.01% 8714
2023
Q2 		– Sell
-668
Closed -$2.94K – 9539
2023
Q1 		$2.94K Sell
668
-25
-4% -$158 ﹤0.01% 8414
2022
Q4 		$4.09K Buy
693
+543
+362% +$4.96K ﹤0.01% 9388
2022
Q3 		$1K Buy
150
+50
+50% +$496 ﹤0.01% 10021
2022
Q2 		$1K Sell
100
-41
-29% -$861 ﹤0.01% 9949
2022
Q1 		$6K Sell
141
-454
-76% -$21K ﹤0.01% 8987
2021
Q4 		$47K Buy
+595
New +$55.8K ﹤0.01% 6964
2021
Q3 		– Sell
-148
Closed -$15K – 10003
2021
Q2 		$15K Buy
148
+61
+70% +$6.05K ﹤0.01% 7647
2021
Q1 		$9K Buy
+87
New +$8.7K ﹤0.01% 8019

Other funds holding SABS

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Polymer Capital Management (HK)
Polymer Capital Management (HK) Hong Kong $1.06B AUM 138.97% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

UBS Group's SABS Position: Q3 2026 in Review

UBS Group increased its SAB Biotherapeutics (SABS) stake by 45% in Q3 2026, buying an estimated $599K and bringing the position to 530,587 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #5174.

UBS Group first reported a position in SABS in Q1 2021 and has held it in 17 quarters since. 45 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • UBS Group held 530,587 shares of SAB Biotherapeutics worth $1.68M as of Q3 2026.
  • UBS Group bought 164,709 SAB Biotherapeutics shares in Q3 2026, an estimated $599K.
  • SAB Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #5174 holding.
  • UBS Group first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 17 quarters since.
  • 45 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.